ストックスクリーナーアプリを入手
0.8839
5.18%
-0.0483
プレマーケット:
.92
0.0361
+4.08%
Rani Therapeutics Holdings Inc (RANI) 最新ニュース
MSN Money - MSN
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Alireza Javadi Net Worth (2026) - GuruFocus
Rani Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Rani Therapeutics (NASDAQ: RANI) sets 2026 virtual meeting on board elections and auditor - Stock Titan
[ARS] Rani Therapeutics Holdings, Inc. SEC Filing - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street Capital - MarketBeat
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor By Investing.com - Investing.com Nigeria
Rani Therapeutics appoints Sara Kenkare-Mitra as advisor - Investing.com
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy - The Manila Times
Drug approval veteran joins Rani to shape oral biologics push - Stock Titan
Update Report: Can Rani Therapeutics Holdings Inc reach all time highs this yearPortfolio Update Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Is Rani (RANI) Stock a Good Buy in 2026 | Price at $0.82, Up 0.86%Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Published on: 2026-04-07 19:26:18 - baoquankhu1.vn
Is Rani (RANI) Stock Stronger Than Peers | Price at $0.88, Up 4.41%Elite Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
RANI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00 - MarketBeat
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Market Review: Can Rani Therapeutics Holdings Inc reach all time highs this yearSwing Trade & Safe Entry Zone Tips - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc beat the S P 5002026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Loss Report: Is Rani Therapeutics Holdings Inc likely to announce a buybackMarket Risk Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Equities Analysts Offer Predictions for RANI Q1 Earnings - MarketBeat
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth - Yahoo Finance
Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Javadi Alireza - Moomoo
Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings - stocktitan.net
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Vanguard disaggregates holdings; reports 0 RANI shares (RANI) - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Given "Buy" Rating at HC Wainwright - MarketBeat
Rani Therapeutics 2025 Annual Report: Oral Biologics Pipeline, Clinical Updates, and Risk Factors 535657 - Minichart
Earnings Call Summary | Rani Therapeutics(RANI.US) Q4 2025 Earnings Conference - news.futunn.com
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast - Investing.com Australia
Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast By Investing.com - Investing.com South Africa
Rani Therapeutics Q4 Earnings Call Highlights - MarketBeat
Rani Therapeutics Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
RANI: Major Chugai deal, RT-114 clinical progress, and strengthened finances mark a transformative 2025 - TradingView
RANI: Advanced pipeline, secured major Chugai deal, and extended cash runway into Q4 2027 - TradingView
Rani Therapeutics 2025 10-K: $1.63M revenue, $(0.45) EPS - TradingView
RANI: Net loss improved to $41.0M in 2025, with $49.7M cash and strengthened by a $60.3M private placement - TradingView
Rani Therapeutics (NASDAQ: RANI) boosts cash, advances oral biologics pipeline - Stock Titan
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results - MarketBeat
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - The Manila Times
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event - Stock Titan
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):